Critical Gaps in FSG
Critical Gaps in FSGS Treatment Highlight Need for New Therapies, with Pipeline Assets from Travere, Vertex, and Dimerix Poised to Address Unmet Needs
01 nov. 2024 09h17 HE | Spherix Global Insights
EXTON, PA, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Focal segmental glomerulosclerosis (FSGS), one of the most common glomerular diseases seen by nephrologists, ranks among the top three rare kidney...
US Rheumatologists a
US Rheumatologists and Dermatologists Report Over Half of their Dermatomyositis Patients Not Optimally Managed, According to Spherix Global Insights
18 oct. 2024 10h56 HE | Spherix Global Insights
EXTON, PA, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Dermatomyositis (DM) is a rare inflammatory disease characterized by muscle weakness and a distinctive skin rash. Currently, the standard of care...
Shifts in the Psoria
Shifts in the Psoriasis Market Suggest Strong Potential for Emerging Oral Therapies
16 oct. 2024 14h48 HE | Spherix Global Insights
EXTON, PA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Biologics have long been the cornerstone of psoriasis (PsO) treatment, valued for their proven efficacy and safety. However, the growing demand for...
Hemophilia Markets P
Hemophilia Markets Poised for Evolution as Competitive Dynamics between Hemlibra (Roche/Genentech) and Altuviiio (Sanofi) Intensify and Hympavzi (Pfizer) Receives Approval, According to Spherix Global Insights
14 oct. 2024 12h33 HE | Spherix Global Insights
EXTON, PA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Hemophilia, a genetic disorder that impairs blood clotting, affects thousands of people worldwide. The treatment landscape is rapidly evolving, fueled by...
Roche/Genentech’s Ga
Roche/Genentech’s Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results
10 oct. 2024 10h28 HE | Spherix Global Insights
EXTON, PA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- While GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have been important advances in the treatment arsenal for lupus nephritis (LN), a...
US Rheumatologists I
US Rheumatologists Identify BAFF-R Inhibitors as the Most Promising Treatment Approach for Sjögren’s Disease, According to Spherix Global Insights
02 oct. 2024 12h27 HE | Spherix Global Insights
EXTON, PA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Sjögren’s disease is a systemic autoimmune rheumatic condition that can profoundly affect a patient's overall functioning. Common symptoms include...
Exciting Advances in
Exciting Advances in Ulcerative Colitis Treatments: Skyrizi Gains Early Momentum Following FDA Approval in June
01 oct. 2024 10h51 HE | Spherix Global Insights
EXTON, PA, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The past twelve months have been transformative for the rapidly evolving ulcerative colitis (UC) market, with a surge in advanced therapies receiving FDA...
Spherix Global Insig
Spherix Global Insights Expands into Financial Services, Empowering Asset Managers and Hedge Funds with Critical Pharmaceutical Market Insights
25 sept. 2024 08h16 HE | Spherix Global Insights
EXTON, PA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights, a leading independent market intelligence and advisory firm, is expanding its specialized offerings to buy-side financial firms...
Despite Projections
Despite Projections of a 2024 Adalimumab Biosimilar Boom, Humira Remains Dominant for Now, According to Spherix Global Insights
23 sept. 2024 10h18 HE | Spherix Global Insights
EXTON, PA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights compiled data from their RealTime Dynamix™ services in Crohn’s Disease, Rheumatoid Arthritis, and Psoriasis, fielded in late...
US Rheumatologists B
US Rheumatologists Believe Biogen’s Litifilimab Is the Leading SLE Pipeline Asset Poised to Offer Improvement Over Benlysta and Saphnelo Based on Clinical Trial Data
12 sept. 2024 16h36 HE | Spherix Global Insights
EXTON, PA, Sept. 12, 2024 (GLOBE NEWSWIRE) -- The systemic lupus erythematosus (SLE) advanced treatment landscape is poised for evolution, with multiple new therapies in development to treat this...